Contact Us
Contact Us
Contact Us


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

10/03/2020Race further strengthens Clinical Advisory BoardDownload
06/03/2020Race Secures A$1.8m strategic placementDownload
06/03/2020Proposed issue of Securities - RACDownload
06/03/2020Dr John Cullity appointed Non-Executive ChairmanDownload
04/03/2020Trading HaltDownload
02/03/2020Appendix 3Y-Dr Daniel TillettDownload
27/02/2020Appendix 2ADownload
27/02/2020Cleansing NoticeDownload
25/02/2020Appendix 4D & Half-Year Financial StatementsDownload
20/02/2020Race significantly strengthens Clinical Advisory BoardDownload
1  2  3  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier